Aurora Cannabis is reporting record international medical cannabis revenue as its proposed acquisition by Organigram Global moves toward completion. In its fiscal second-quarter 2027 results, covering the three months ended September 30, 2026, the company reported C$86.0 million in net revenue, up 9% from the same quarter last year.
International Medical Cannabis Drives Record Revenue
International medical cannabis generated a record C$61.4 million, representing a 44% increase from the same quarter a year earlier.
Aurora attributed the growth primarily to stronger performance in Germany and Poland.
The company also reported adjusted EBITDA of C$14.0 million, a non-GAAP measure — down from C$15.4 million a year earlier — and ended the quarter with C$133 million in cash, cash equivalents and short-term investments and no debt.
Despite the revenue growth, Aurora reported a C$21.1 million net loss from continuing operations, narrowed from C$27.2 million in the same quarter last year.
Canadian Medical and Consumer Sales Decline
The company's domestic results were weaker.
Canadian medical cannabis revenue fell to C$21.2 million, down from C$27.9 million a year earlier, following changes to federal reimbursement.
Consumer cannabis revenue declined to C$1.6 million as Aurora continues winding down that business.
Wholesale bulk cannabis revenue rose to C$1.9 million, from C$1.0 million in the same quarter last year.
The results show a contrast between the company's expanding international medical operations and its declining Canadian medical and consumer revenue.
Organigram Acquisition Moves Forward
The companies announced a definitive arrangement agreement on November 3, 2026, under which Organigram will acquire Aurora for C$7.80 per share. The transaction is valued at approximately C$561 million on a fully diluted basis and is expected to close in January 2027, subject to shareholder, court and regulatory approvals. Aurora shareholders will be able to elect cash, Organigram shares or a combination, subject to proration.
Aurora Cancels November Investor Call
Aurora also cancelled its investor call scheduled for November 12 because of the pending acquisition.
The company's second-quarter results therefore arrive as the proposed transaction moves toward its expected January 2027 closing.
All financial figures are as reported by Aurora in its earnings release. Any growth outlooks included in the release represent the company's own forward-looking statements.
Sources
- Aurora Cannabis Inc. Fiscal 2027 Second-Quarter Results. November 5, 2026. Reports financial results for the quarter ended September 30, 2026, including net revenue, international medical sales, adjusted EBITDA, net loss, cash position and Canadian revenue.
- Organigram Global and Aurora Cannabis. Definitive Arrangement Agreement Announcement. November 3, 2026. Supports the acquisition agreement, C$7.80-per-share consideration, approximately C$561 million fully diluted valuation and expected January 2027 closing.
0 comments